Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + lenvatinib + capecitabine first-line study in advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy
ChiCTR2300068266Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, lenvatinib and capecitabine in intrahepatic cholangiocarcinoma (ICC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Six-month progression-free survival rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
tislelizumablenvatinibcapecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2300068266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068266.